Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs

ABSTRACT Aims Drug‐induced liver injury (DILI) is a major global health concern resulting from adverse reactions to medications, supplements or herbal medicines. The relevance of DILI has grown with an aging population, the rising prevalence of chronic diseases and the increased use of biologics, including checkpoint inhibitors. This article aims to summarise current knowledge on DILI epidemiology and risk factors. Methods This review critically appraises available evidence on DILI frequency, outcomes and risk determinants, focusing on drug properties and non‐genetic host factors that may influence susceptibility. Results DILI incidence varies across populations, with hospitalised patients experiencing notably higher rates than outpatients or the general population. Increased medication use, particularly among older adults and women, may partly explain age‐ and sex‐based disparities in DILI incidence and reporting. Physiological changes associated with aging likely increase susceptibility to DILI in older adults, though further exposure‐based studies are needed for definitive conclusions. Current evidence does not strongly support that women are inherently more susceptible to DILI than men; rather, susceptibility appears to depend on specific drugs. However, once DILI occurs, older age and female sex are associated with greater severity and poorer outcomes. Other less‐studied host‐related risk factors are also discussed based on available evidence. Conclusions This article summarises existing data on DILI frequency, outcomes, drug properties affecting hepatotoxicity and non‐genetic host risk factors while identifying critical knowledge gaps. Addressing these gaps through future research could enhance understanding and support preventive measures.